
    
      between March 2013 and March 2014, patients who were unresponsive to therapy with
      corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity
      Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection
      subcutaneously twice a week. The follow-up time of the study was 24 weeks.
    
  